Skip to main content
Equibles
NASC logo

NASC · Can B Corp

Track NASC — free

Use NASC with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.01 At close · Aug 28
Rebalance outlook locked
Market Cap
$606,736
Shares
75.84M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.01 Open$0.01 Day$0.01–0.01 52W close$0.01–0.04 Avg vol 30d62K Short int696 · 0.0% float · 1.0d Short vol99% DataFeb 2022–Aug 2026 Filing10-Q · Nov 19

Raw chart and full-history price indicators begin at the captured split on Feb 14, 2022; bars on opposite sides are not compared.

Up next

Latest filing: 10-Q
filed Nov 19, 2024

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.03M
Trailing 12 months
Net income (TTM)
−$13.26M
Trailing 12 months
Revenue growth YoY
-96.4%
Year over year
Operating margin
-1,035.9%
Trailing 12 months
P / E (TTM)
0.1
Trailing earnings · reciprocal yield 843.4%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$7,879
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+464.6%
Year over year · more shares
Price change (1Y)
-44.7%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.2 · calm Equity put/call 0.56
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −51%
below
Price vs 50-day avg −36%
below
RSI (14) 42
neutral
MACD trend Negative
52-week position 5%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −36%
trailing
6-month return −54%
trailing
YTD return −48%
this year
Relative strength −67%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
0% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.00% of float · ▲ +69500.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1 holders — 13F breadth
Squeeze score 16
low risk · 0–100
Fundamentals
Strong
Revenue growth +29%
Y/Y
Gross margin 292%
contracting
EPS growth +82%
Y/Y
Free cash flow $-1.3M
Quant / Vol
risk profile
Very High
Volatility 223%
annualized · 1-yr
Max drawdown −81%
past year
ATR 25.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−51% Bearish
Price vs 50-day avg
−36% Bearish
RSI (14)
42 Neutral
MACD trend
Negative Bearish
52-week position
5% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
0% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.00% of float · ▲ +69500.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1 holders — 13F breadth
Price context
position in its 52-week range
Range low $0 Now $0 · 5% Range high $0
vs 200-day avg -51% vs 50-day avg -36%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NASC
Can B Corp
this stock
$606,736 -48.1% +29.0% — 0.0%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
 $66.37B — — — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
 $58.66B +18.2% — — 0.1%
GALDY
Galderma Group AG/ADR
 $47.50B -1.7% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $43.03B +20.1% +4.3% 60.5 3.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders
Holders
1
% held
0.0%
Net QoQ
0 sh
Top holder
Byrne Asset Management LLC
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
696
Days to cover
1.0d
Change
+695 sh
View
Short Volume
Short vol %
99%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
5.6K
Value
$112
As of
Apr 10, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$2.2M
Net income (FY)
$-9.7M
EPS diluted
$-0.77
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 19, 2024
This year
0
View
Exempt Offerings
Offering
$2.8M
Filed
Dec 21, 2020
View

Performance

Raw-price comparisons begin at the captured split on Feb 14, 2022; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
NASC -11.7% -36.2% -53.9% -44.7% -48.1%
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY -12.2% -39.1% -67.3% -47.7% -60.9%
Key facts CIK 1509957 CUSIP 63108T105 Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)